K. Späthe

Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

A. Burges, F. Hilpert, A. Bois, 2005, Supportive Care in Cancer.

Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.

E. Lengyel, M. Schmitt, W. Kuhn, 2001, Gynecologic oncology.

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.

E. Lengyel, M. Schmitt, W. Kuhn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ovarian Prognostic Significance of Urokinase (upa) and Its Inhibitor Pai-1 for Survival in Advanced Ovarian Carcinoma Stage Figo Iiic

H. Höfler, N. Harbeck, P. Dettmar, 2022 .

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

K. Ulm, W. Kuhn, H. Graeff, 2001 .

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.

K. Ulm, W. Kuhn, H. Graeff, 2001, Cancer.

The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV

K. Ulm, J. Siewert, F. Jänicke, 1998 .

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

H. Höfler, N. Harbeck, P. Dettmar, 1999, British Journal of Cancer.